Fig. 3. RBN inhibited CD38 expression in vitro and in vivo models of NAFLD through mediating p300, acetyltransferase. (A) The publicly available BioAssay database for the bioactivities of RBN. AID, Assay ID. (B) Total RNA was extracted from the cells, and CD38 expression was measured using qRT-PCR. The results are demonstrated as the relative fold change of the control, and the values presented are the means ± SD of three independent experiments. The means with different superscript letters are significantly different, p<0.05 (one-way ANOVA). (C, D) For 12-week RBN supplementation with WD, mouse liver tissues were collected, and total RNA was extracted from them. Total RNA was used for cDNA synthesis, following which CD38 mRNA expression was measured. Data are presented as the means ± SE (n=4/each group). The means with superscript letters are significantly different, p<0.05 (one-way ANOVA) (C). Additionally, the protein expression of CD38 was observed using western blot assays. The intensity of each band indicating CD38 expression was normalized to that of the internal control HSP90αβ (D, left panel). The average quantified values for the protein expression of CD38 for each group are presented (D, right panel). (E) siRNAs against either p300 or pCAF were transiently transfected into AML-12 cells, and the cells were incubated 12 h after the transfection. After 24 h following OPA treatment, the cells were harvested, and the CD38, p300, and pCAF mRNA expression levels were determined using qRT-PCR. (F) AML-12 cells were exposed to OPA w/wo a p300 specific inhibitor, C-646, at the indicated concentrations for 18 h. The total RNA was extracted from the cells, and CD38 expression was measured using qRT-PCR. The results are demonstrated as the relative fold change of the control values, and the values are presented as the means ± SD of three independent experiments. The means with different superscript letters are significantly different, p<0.05 (one-way ANOVA).
© Biomolecules & Therapeutics
